NeuroPn Therapeutics is working on soluble epoxide hydrolase (sEH) inhibitors to develop novel therapies for the treatment of neurodegenerative diseases with focus on painful peripheral neuropathy and Parkinson’s disease.
sEH inhibition as a validated, multi-modal therapy for pain and neurodegenerative diseases
Painful Peripheral Neurotheraphy
Inadequate efficacy and mechanism-based side effects continue to restrict the utility of marketed drugs for chronic neuropathic pain. Selective stimulation of the endogenous analgesic pathway that mimics a natural response to pain stimuli could yield novel agents with superior efficacy and reduced side effects over marketed drugs.
sEH inhibition stimulates endogenous pathways for pain relief and promotes nerve healing >
Soluble epoxide hydrolase (sEH) is a regulatory enzyme that rapidly
degrades protective mediators epoxyeicosatrienoic acids (EETs) to
inactive dihydroxyeicosatrienoic acids (DHETs). Inhibition of sEH
stimulates endogenous GABAergic and opioid pathways to provide
effective pain relief without narcotic effects. Inhibitors of sEH
reduce endoplasmic reticulum (ER) and oxidative stress, neuronal
inflammation and neurodegeneration.
NeuroPn sEH-inhibitors provide a novel, non-narcotic, disease-modifying therapy for chronic neuropathic pain conditions.
Parkinson’s Disease (PD)
Neuroinflammation and mitochondrial dysfunction with associated oxidative/endoplasmic reticulum (ER) stress all work synergistically to accelerate Parkinson’s disease (PD) progression.
Emergent data supports a crucial role of soluble epoxide hydrolase
(sEH) in driving pathogenesis of human PD. sEH promotes neuronal
inflammation, a-synuclein aggregation, neurotoxicity and death of
dopaminergic neurons -
NeuroPn is pursuing novel inhibitors of soluble epoxide hydrolase (sEH) to develop disease modifying therapeutics for Parkinson’s disease with highly discriminatory (efficacy, safety, neuronal protection) vs. marketed drugs.